Ro, Novo Nordisk Collaborate on Wegovy Savings

Ro, a direct-to-patient healthcare company, has partnered with Novo Nordisk to offer significant savings on Wegovy®. Patients can now save up to $1,200 annually on the Wegovy® pen or $600 per year through this collaboration. This initiative aims to increase affordable access to the popular weight-loss medication, making it more attainable for individuals managing their health and weight. The program highlights a growing trend of pharmaceutical companies working with healthcare providers to improve patient affordability and adherence to prescribed treatments.